World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
104
Citations
74423
World Ranking
6882
National Ranking
207

Fabrice Barlesi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Fabrice Barlesi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 922 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Fabrice Barlesi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Fabrice Barlesi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 104 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Fabrice Barlesi is affiliated with the Institut Gustave Roussy in France. Their work primarily focuses on Medicine, with significant contributions to Oncology, Pulmonary and Respiratory Medicine, and Cancer Research among other related fields. The research spans subfields including Radiology, Nuclear Medicine and Imaging, and Molecular Biology.

Their research topics encompass a range of subjects related to cancer and respiratory diseases. Key areas of work include:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Diagnosis and Treatment
  • COVID-19 and healthcare impacts

Frequent collaborators in their research include:

  • Benjamin Besse (114 co-authored publications)
  • David Planchard (75 co-authored publications)
  • Mihaela Aldea (54 co-authored publications)
  • Julien Mazières (47 co-authored publications)
  • Anas Gazzah (39 co-authored publications)

Fabrice Barlesi has published extensively in respected journals with a consistent presence in several key venues. These include:

  • Annals of Oncology (71 publications)
  • Journal of Clinical Oncology (53 publications)
  • Journal of Thoracic Oncology (43 publications)
  • Cancer Research (31 publications)
  • Lung Cancer (13 publications)

Notable recent papers related to their field of study include:

  • "KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors," 2020, New England Journal of Medicine
  • "Sotorasib for Lung Cancers with KRAS p.G12C Mutation," 2021, New England Journal of Medicine
  • "Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group," 2020, Annals of Oncology
  • "Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19," 2020, Cell
  • "Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer," 2020, New England Journal of Medicine

Best Publications

  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

    H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

    Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  • Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Mark A. Socinski;Robert M. Jotte;Federico Cappuzzo;Francisco Orlandi

  • Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †

    S Novello;F Barlesi;R Califano;R Califano;T Cufer

  • Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

    Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski

  • Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

    Thomas J. Lynch;Igor Bondarenko;Alexander Luft;Piotr Serwatowski

  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

    David S. Hong;Marwan G. Fakih;John H. Strickler;Jayesh Desai

  • Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

    Ferdinandos Skoulidis;Bob T. Li;Grace K. Dy;Timothy J. Price

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

    Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  • Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

    Martin Reck;Tony S K Mok;Makoto Nishio;Robert M Jotte

  • Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

    Fabrice Barlesi;Julien Mazieres;Jean-Philippe Merlio;Didier Debieuvre

  • Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.

    F. Mosele;J. Remon;J. Mateo;C. B. Westphalen

  • Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.

    Aymeric Silvin;Nicolas Chapuis;Garett Dunsmore;Anne-Gaëlle Goubet

  • An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

    David Planchard;Benjamin Besse;Harry J M Groen;Pierre-Jean Souquet

  • Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

    M. Reck;I. Bondarenko;A. Luft;P. Serwatowski

  • Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

    Benjamin Besse;Mélinda Charrier;Valérie Lapierre;Eric Dansin

  • Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

    Julien Mazières;Solange Peters;Benoit Lepage;Alexis B. Cortot

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.

    Pascale Tomasini;Laurent Greillier;Arnaud Boyer;Arnaud Jeanson

Frequent Co-Authors

Julien Mazieres
Julien Mazieres Paul Sabatier University
Benjamin Besse
Benjamin Besse University of Paris-Saclay
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Jacques Cadranel
Jacques Cadranel Université Paris Cité
Pascal Thomas
Pascal Thomas Aix-Marseille University
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Jean-Charles Soria
Jean-Charles Soria Amgen (United States)
Byoung Chul Cho
Byoung Chul Cho Yonsei University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t have to mean committing only to the role of a physician. There are a variety of online degrees and pathways for those interested in healthcare. The rise in distance learning has opened doors to advanced healthcare roles and leadership positions — all accessible online.

For those interested in mental health and patient care, pmhnp online programs prepare nurses for specialized psychiatric and mental health roles. If your passion is leading within healthcare organizations, an online health management degree emphasizes the skills needed for efficient hospital and clinic operations.

Cost-conscious students can explore the cheapest online mha programs for a focused master's in healthcare administration, giving access to upper management positions. Alternatively, if you’re aiming for the highest levels of nursing practice, the cheapest dnp programs online make earning a Doctor of Nursing Practice more accessible than ever.

Collectively, these online pathways offer flexibility and affordability, giving aspiring healthcare professionals a range of options beyond traditional medical degrees.

Best Scientists Citing Fabrice Barlesi

Trending Scientists

Recently Published Articles